Stemline Therapeutics, Inc.

Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

	The Company
	Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells.

	Platform
	Stemline Therapeutics has developed a Discovery Platform called StemScreen^® to identify novel compounds that target and kill CSCs.

News
&
Events

5/22/2013
Stemline Announces Closing of $60 Million Public Offering of Common Stock

5/16/2013
Stemline Therapeutics Prices $60 Million Public Offering of Common Stock

4/25/2013
Stemline to Present at the 12th Annual Needham Healthcare Conference on May 1